PT - JOURNAL ARTICLE AU - Nicholas Edward Phillips AU - Julie Mareschal AU - Nathalie Schwab AU - Emily N.C. Manoogian AU - Sylvie Borloz AU - Giada Ostinelli AU - Aude Gauthier-Jaques AU - Sylvie Umwali AU - Elena Gonzalez Rodriguez AU - Daniel Aeberli AU - Didier Hans AU - Satchidananda Panda AU - Nicolas Rodondi AU - Felix Naef AU - Tinh-Hai Collet TI - The effects of time-restricted eating vs. standard dietary advice on weight, metabolic health and the consumption of processed food: A pragmatic randomised controlled trial in community-based adults AID - 10.1101/2021.01.29.21250725 DP - 2021 Jan 01 TA - medRxiv PG - 2021.01.29.21250725 4099 - http://medrxiv.org/content/early/2021/02/01/2021.01.29.21250725.short 4100 - http://medrxiv.org/content/early/2021/02/01/2021.01.29.21250725.full AB - The prevalence of metabolic syndrome (MS) is increasing, affecting approximately 1 billion people. Weight loss is key to control MS components, i.e. central obesity, hypertension, prediabetes, and dyslipidaemia. Here, we characterised the relationships between eating duration, unprocessed and processed food consumption, and metabolic health. In a 4-week observation phase, 213 Swiss adults recorded consumed meals and drinks with a smartphone application, and these were annotated for food processing levels according to the NOVA classification. Regression analysis showed that consumption of unprocessed food items showed the highest number of significant relationships with MS components after age and sex. The fraction of unprocessed food out of all ingestion events was positively associated with HDL cholesterol and negatively associated with BMI, waist circumference and triglycerides. Next, in a pragmatic randomised controlled trial, we tested whether 12h time-restricted eating (TRE) leads to metabolic benefits compared to standard dietary advice (SDA), in 54 adults who ate >14h per 24h cycle and had at least one MS component. After 6 months, those randomised to TRE lost 1.6% of initial body weight (SD 2.9, p = 0.01), compared to the absence of weight loss with SDA (−1.1%, SD 3.5, p = 0.19). Thus, there was no significant difference in weight loss between TRE and SDA (between-group difference −0.5 kg, 95% confidence interval −2.4 to 1.4, p = 0.61). Overall, our results show the potential of smartphone records to predict metabolic health, and highlight that further research is needed to understand individual response to TRE and SDA.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT03241121Funding StatementThis research was funded by the Swiss National Science Foundation (grant no PZ00P3-167826 to T.H.C.), the Swiss Society of Endocrinology and Diabetes (2017 Young Investigator prize to T.H.C.), and the Strategic Focal Area Personalized Health and Related Technologies (PHRT) of the ETH Domain (grant no 2018-427 to N.E.P.). T.H.C.'s research is also supported by grants from the Leenaards Foundation, the Vontobel Foundation, and the Swiss Multiple Sclerosis Society. D.A.'s research is supported by the Novartis Foundation for bio-medical research and the Alfred und Anneliese Sutter-Stöttner Stiftung. G.O. is the recipient of a doctorate scholarship by the Fonds de recherche Québec Santé (FRQS).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was conducted according to the guidelines of the Declaration of Helsinki and the Good Clinical Practice. It was approved by the Ethics Committees of Vaud canton and Bern canton, Switzerland (protocol no 2017-00487).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data presented in this study are available upon reasonable request to the corresponding author. The data are not publicly available due to confidentiality reasons.